Breast Cancer Diagnostics Market Report 2026 Market Outlook Supported By A Forecast 7.7% CAGR

The breast cancer diagnostics sector is on the verge of significant expansion, driven by technological advancements and increasing demand for precise and early detection methods. As healthcare providers and patients alike seek more accurate and less invasive diagnostic options, this industry is set for notable progress. Below, we explore the market size projections, key players, major trends, and segment-specific insights shaping the future of breast cancer diagnostics.

Projected Market Size and Growth Outlook for the Breast Cancer Diagnostics Market
The breast cancer diagnostics market is expected to experience robust growth over the coming years, reaching a market value of $7.28 billion by 2030. This represents a compound annual growth rate (CAGR) of 7.7%, fueled by greater adoption of precision oncology diagnostics and increasing investments in AI-powered diagnostic platforms. Additional growth drivers include rising demand for minimally invasive testing, the expansion of population-based screening initiatives, and ongoing innovations in molecular diagnostic technologies. Key trends anticipated during this period involve the widespread adoption of AI-assisted imaging analyses, enhanced use of genomic and molecular tests, increased implementation of liquid biopsy techniques, development of advanced non-ionizing imaging methods, and a stronger focus on early, personalized diagnosis.

Download a free sample of the breast cancer diagnostics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Companies Shaping the Breast Cancer Diagnostics Industry
The breast cancer diagnostics market is dominated by several prominent organizations, including Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, and Veracyte Inc.

Significant Industry Moves Enhancing Breast Cancer Diagnostics
In July 2024, Hologic Inc., a US-based healthcare technology company, acquired Endomagnetics Ltd. for $310 million. This strategic acquisition aims to strengthen Hologic's breast surgery offerings by incorporating Endomag's cutting-edge wireless localization and lymphatic tracing technologies. Endomagnetics Ltd., headquartered in the UK, specializes in advanced breast cancer diagnostic solutions, including tissue localization and lymphatic mapping systems, which will complement Hologic's existing portfolio.

View the full breast cancer diagnostics market report:
https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Key Trends Driving Innovation and Opportunities in Breast Cancer Diagnostics
Companies in the breast cancer diagnostics field are increasingly focused on developing AI-based diagnostic tools that improve accuracy, streamline workflow, and support personalized treatment strategies. AI-powered platforms utilize machine learning and deep learning algorithms to analyze medical imaging, pathology slides, and clinical data, providing risk stratifications and diagnostic insights that aid clinical decisions.

For example, in September 2024, Ibex Medical Analytics, an Israeli digital pathology firm, launched an upgraded AI platform for breast cancer that includes a fully automated zero-click HER2 immunohistochemistry (IHC) scoring feature in its Ibex Breast HER2 module. This tool accurately identifies invasive cancer regions, categorizes HER2 expression levels (0, 1+, 2+, 3+), and assists in refining breast cancer diagnoses and treatment pathways, enhancing both precision and efficiency.

Market Segmentation and Forecast Analysis in Breast Cancer Diagnostics
This report divides the breast cancer diagnostics market into distinct segments as follows:

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types
2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies
3) By Cancer Type: BRCA Breast Cancer, ER and PR Breast Cancer, HER2 Breast Cancer, Triple-Negative Breast Cancer, Other Cancer Types
4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies
5) By End Users: Hospitals and Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Further breakdowns include:
- Imaging subcategories such as Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Tomosynthesis.
- Biopsy types including Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), and Stereotactic Biopsy.
- Genomic tests like Oncotype DX, MammaPrint, PAM50, and BRCA1 or 2 Testing.
- Blood tests encompassing Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, and Circulating Tumor Cells (CTCs) Tests.
- Other diagnostic types including Hormone Receptor Tests, HER2 Tests, and Genetic Mutation Testing.

Together, these detailed segments provide a comprehensive framework for understanding market dynamics, guiding investments, and fostering innovation in breast cancer diagnostics.

Expanded capabilities in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.